Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers

Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1235-7. doi: 10.1097/MEG.0b013e328305ba2a.

Abstract

This observation reports that a hepatitis B virus (HBV) reactivation, as the result of hepatitis C virus (HCV) eradication on a dominant HCV coinfected HBV/HCV patient, was subsequently prevented by treating both viral infections together. This finding raises the question as to whether preemptive HBV treatment should be prescribed along with HCV treatment to prevent HBV from being reactive after HCV eradication in coinfected HBV/HCV patients.

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Adult
  • Antiviral Agents / therapeutic use*
  • Carrier State / drug therapy
  • Carrier State / virology
  • Drug Therapy, Combination
  • Hepatitis B / complications
  • Hepatitis B / drug therapy
  • Hepatitis B / prevention & control*
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / physiology*
  • Hepatitis C / complications
  • Hepatitis C / drug therapy*
  • Humans
  • Male
  • Organophosphonates / therapeutic use*
  • Virus Activation / drug effects*

Substances

  • Antiviral Agents
  • Organophosphonates
  • adefovir
  • Adenine